CTSO Quote, Financials, Valuation and Earnings

Exact Sciences has a net margin of -16.94% compared to CytoSorbents's net margin of -14.32%. CytoSorbents's return on equity of -106.57% beat Exact Sciences's return on equity of -35.57%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 474.71%. On the other hand Exact Sciences has an analysts' consensus of $68.83 which suggests that it could grow by 20.99%. Given that CytoSorbents has higher upside potential than Exact Sciences, analysts believe CytoSorbents is more attractive than Exact Sciences.

CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.920, suggesting its less volatile than the S&P 500 by 7.968%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.7M, which are smaller than Exact Sciences quarterly revenues of $706.8M. CytoSorbents's net income of -$1.5M is higher than Exact Sciences's net income of -$101.2M. Notably, CytoSorbents's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.38x versus 3.73x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -16.94% compared to CytoSorbents's net margin of 12.58%. CytoSorbents's return on equity of -106.57% beat Illumina's return on equity of -34.38%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 474.71%. On the other hand Illumina has an analysts' consensus of $106.53 which suggests that it could grow by 34.22%. Given that CytoSorbents has higher upside potential than Illumina, analysts believe CytoSorbents is more attractive than Illumina.

CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Illumina has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.945%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.7M, which are smaller than Illumina quarterly revenues of $1B. CytoSorbents's net income of -$1.5M is lower than Illumina's net income of $131M. Notably, CytoSorbents's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.38x versus 2.91x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Natera has a net margin of -16.94% compared to CytoSorbents's net margin of -13.34%. CytoSorbents's return on equity of -106.57% beat Natera's return on equity of -19.19%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 474.71%. On the other hand Natera has an analysts' consensus of $191.91 which suggests that it could grow by 27.02%. Given that CytoSorbents has higher upside potential than Natera, analysts believe CytoSorbents is more attractive than Natera.

CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Natera has a beta of 1.794, suggesting its more volatile than the S&P 500 by 79.445%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.7M, which are smaller than Natera quarterly revenues of $501.8M. CytoSorbents's net income of -$1.5M is higher than Natera's net income of -$66.9M. Notably, CytoSorbents's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.38x versus 10.58x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -16.94% compared to CytoSorbents's net margin of -9.1%. CytoSorbents's return on equity of -106.57% beat Star Equity Holdings's return on equity of -15.99%.

CytoSorbents has a consensus price target of $5.00, signalling upside risk potential of 474.71%. On the other hand Star Equity Holdings has an analysts' consensus of $8.50 which suggests that it could grow by 291.72%. Given that CytoSorbents has higher upside potential than Star Equity Holdings, analysts believe CytoSorbents is more attractive than Star Equity Holdings.

CytoSorbents has a beta of 1.171, which suggesting that the stock is 17.12% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.92%.

CytoSorbents has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

CytoSorbents quarterly revenues are $8.7M, which are smaller than Star Equity Holdings quarterly revenues of $12.9M. CytoSorbents's net income of -$1.5M is lower than Star Equity Holdings's net income of -$1.2M. Notably, CytoSorbents's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents is 1.38x versus 0.12x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.